EpCAM overexpression in thyroid carcinomas - A histopothological study of 121 cases
EpCAM overexpression in thyroid carcinomas - A histopothological study of 121 cases
复制标题
DOI：
10.1097/01.cji.0000211303.52503.da
复制
发表时间：
2006-09-01
影响因子：
3.9
通讯作者：
Schmid, Kurt W.
中科院分区：
文献类型：
--
作者：
Ensinger, Christian;Kremser, Roswitha;Schmid, Kurt W.
上皮细胞粘附分子（Epithelial cell adhesion molecule, EpCAM）在多种癌细胞中表达。它得到了单克隆抗体17-1A的认可，已经在临床前和小型临床研究中应用于几种类型癌症的免疫治疗。本研究对121例滤泡性甲状腺癌的17-1A免疫组化特性进行了评价，其中分化型甲状腺癌75例，乳头状甲状腺癌35例，滤泡性甲状腺癌40例，低分化型甲状腺癌24例，间变性甲状腺癌22例。最近定义的EpCAM过表达81.3%的dtc和66.6%的pdtc具有明显的膜性染色模式。相比之下，所有间变性甲状腺癌（0%）完全缺乏EpCAM表达。正常甲状腺组织EpCAM染色弱且不均匀。本研究表明EpCAM过表达在dtc和pdtc中普遍存在。因此这些肿瘤可能成为epcam定向免疫治疗的新靶点。我们的研究结果表明，复发或晚期肿瘤疾病和转移性扩散的患者可以从这种现代治疗方案中受益，特别是在放射性碘治疗不足的情况下。
Epithelial cell adhesion molecule (EpCAM) is expressed by a broad variety of carcinoma cells. It is recognized by the monoclonal antibody 17-1A, which has already been applied for immunotherapy of several carcinoma types in preclinical and small clinical studies. In the present study the immunohistochemical properties of 17-1A were evaluated in 121 cases of thyroid carcinomas of follicular cell origin, comprising of 75 differentiated (DTC; 35 papillary and 40 follicular carcinomas), 24 poorly differentiated (PDTC) and 22 anaplastic thyroid carcinomas. Overexpression of EpCAM, as recently defined. was found with a distinct membranous staining pattern in 81.3% of DTCs and in 66.6% of PDTCs. In contrast, all anaplastic thyroid carcinomas (0%) completely lacked EpCAM expression. Normal thyroid tissue presented with weak and heterogeneous EpCAM staining. This study demonstrates EpCAM overexpression as a common finding in DTCs and PDTCs. and thus these tumors as possible novel targets for EpCAM-directed immunotherapy. Our findings suggest that patients with recurrent or advanced tumor disease and metastatic spread could benefit from this modern therapeutic regime, especially after insufficient radioiodine therapy.